Article Sidebar

PDF (Tiếng Việt)
Published: 2025-10-31
Abstract Views: 0
Views PDF (Tiếng Việt): 0
DOI: https://doi.org/10.52852/tcncyh.v195i10.3929
Issue
Vol. 195 No. 10 (2025)
Section
Các bài báo
How to Cite
Mạnh, P. D., Toàn, P. K., & Huy, T. L. (2025). 82. Gefitinib rechallenge After Osimertinib-Induced Interstitial Lung Disease: A Case Report and Literature Review. Journal of Medical Research, 195(10), 795-800. https://doi.org/10.52852/tcncyh.v195i10.3929

82. Gefitinib rechallenge After Osimertinib-Induced Interstitial Lung Disease: A Case Report and Literature Review

Pham Duy Manh, Phan Khanh Toan, Trinh Le Huy

Main Article Content

Abstract

Osimertinib has significantly improved survival time in patients with advanced-stage non-small cell lung cancer (NSCLC) harboring EGFR mutations. However, interstitial pneumonia induced by osimertinib, despite its low incidence, represents a serious adverse effect. Currently, there is no clear guideline regarding the re-administration of Osimertinib or other EGFR inhibitors after patients recover from interstitial pneumonia. We report a clinical case of a 70-years-old male patient with stage IV lung cancer and an EGFR exon 19 deletion mutation, who developed interstitial pneumonia after 3 months of treatment with Osimertinib. The patient was primarily treated with methylprednisolone, and the pneumonia improved thereafter. Gefitinib, a first-generation EGFR inhibitor, was re-administered after stabilization of the interstitial pneumonia, demonstrating safety and efficacy as the patient did not experience drug toxicity and the primary tumor shrank after 7 months of treatment. In addition to the above illustrative example, we conducted an analysis based on a literature review to conclude that first- or second-generation EGFR inhibitors are a safe and effective alternative for NSCLC patients with interstitial pneumonia induced by osimertinib, especially in patients experiencing grade 3-4 toxicities.

Article Details

Keywords

Lung cancer, EGFR inhibitors, interstitial pneumonia

References

1. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. Jan 11 2018; 378(2): 113-125. doi:10.1056/NEJMoa1713137.
2. Sakata Y, Sakata S, Oya Y, et al. Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT). Eur J Cancer. Dec 2021; 159: 144-153. doi:10.1016/j.ejca.2021.09.041.
3. Gemma A, Kusumoto M, Sakai F, et al. Real-World Evaluation of Factors for Interstitial Lung Disease Incidence and Radiologic Characteristics in Patients With EGFR T790M-positive NSCLC Treated With Osimertinib in Japan. J Thorac Oncol. Dec 2020; 15(12): 1893-1906. doi:10.1016/j.jtho.2020.08.025.
4. Chinese Anti-Cancer Association, Committee of Lung Cancer Society. EGFR-TKI ADR Management Chinese Expert Consensus. Chin J Lung Cancer (Chinese) 2019; 22(2): 57-81. doi: 10.3779/j.issn.1009-3419.2019.02.01.
5. Liu X, Ma B, Li T, et al. Case Report: Afatinib-Induced Interstitial Pneumonia: Experiences and Lessons From Two Patients. Front Pharmacol. 2021; 12: 698447. doi:10.3389/fphar.2021.698447.
6. Osako T, Takuwa T, Shindo Y. Life-threatening interstitial lung disease with adjuvant osimertinib after complete resection of non-small cell lung cancer: a case report. AME Case Rep. 2025; 9: 56. doi:10.21037/acr-24-203.
7. Freites-Martinez A, Santana N, Arias-Santiago S, et al. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermosifiliogr (Engl Ed). Jan 2021; 112(1): 90-92. CTCAE versión 5.0. Evaluación de la gravedad de los eventos adversos dermatológicos de las terapias antineoplásicas. doi:10.1016/j.ad.2019.05.009.
8. Kodama H, Wakuda K, Yabe M, et al. Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma. Invest New Drugs. Apr 2021; 39(2): 571-577. doi:10.1007/s10637-020-01005-1.
9. Nishioka N, Imai H, Endo M, et al. Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101). Target Oncol. May 2024; 19(3): 423-433. doi:10.1007/s11523-024-01048-x.
10. Park K, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. May 2016; 17(5): 577-89. doi:10.1016/s1470-2045(16)30033-x.
11. Paz-Ares L, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol. Feb 1 2017; 28(2): 270-277. doi:10.1093/annonc/mdw611.